{"id":"pemetrexed-disodium-for-injection","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Myelosuppression (neutropenia, anemia, thrombocytopenia)"},{"rate":"20-30","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-20","effect":"Mucositis"},{"rate":"10-15","effect":"Diarrhea"},{"rate":"5-10","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pemetrexed disodium is a multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, key enzymes in the folate pathway required for purine and pyrimidine synthesis. By blocking these enzymes, it prevents the formation of nucleotides necessary for DNA and RNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells.","oneSentence":"Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:37.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Malignant pleural mesothelioma"},{"name":"Locally advanced or metastatic urothelial cancer"}]},"trialDetails":[{"nctId":"NCT05017012","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-21","conditions":"Advanced or Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":"Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC","enrollment":30},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT06396065","phase":"PHASE3","title":"Phase III Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Summit Therapeutics","startDate":"2023-05-04","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":420},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT05751187","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-06-27","conditions":"Non-squamous NSCLC","enrollment":54},{"nctId":"NCT06883630","phase":"PHASE1","title":"A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2025-03-13","conditions":"Non-Small Cell Lung Cancer","enrollment":121},{"nctId":"NCT05184712","phase":"PHASE3","title":"Phase 3 Clinical Study of AK112 for NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-01-25","conditions":"Non-Squamous Non-small Cell Lung Cancer","enrollment":322},{"nctId":"NCT06663306","phase":"PHASE1","title":"Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-12-09","conditions":"Lung Cancer (NSCLC), Leptomeningeal Metastasis","enrollment":19},{"nctId":"NCT06772623","phase":"PHASE1, PHASE2","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-03-06","conditions":"Non Small Cell Lung Carcinoma","enrollment":252},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer","enrollment":673},{"nctId":"NCT06236438","phase":"PHASE2, PHASE3","title":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-04-10","conditions":"Non-Small Cell Lung Cancer","enrollment":840},{"nctId":"NCT07418749","phase":"PHASE3","title":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Recurrent Cervical Cancer, Metastatic Cervical Cancer","enrollment":398},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT06956001","phase":"PHASE3","title":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-11-19","conditions":"EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":300},{"nctId":"NCT06783647","phase":"PHASE2","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2025-06-11","conditions":"Advanced Solid Tumour","enrollment":230},{"nctId":"NCT06970639","phase":"PHASE3","title":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-09-26","conditions":"NSCLC Patients With Brain Metastasis","enrollment":380},{"nctId":"NCT04585477","phase":"PHASE2","title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-04-08","conditions":"Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II","enrollment":80},{"nctId":"NCT02662504","phase":"PHASE2","title":"Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2016-01-16","conditions":"Malignant Pleural Mesothelioma","enrollment":6},{"nctId":"NCT07383116","phase":"PHASE3","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2026-01-15","conditions":"Non Squamous Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT07381829","phase":"PHASE1","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-10-27","conditions":"Advanced Solid Tumor Cancer","enrollment":328},{"nctId":"NCT05746481","phase":"PHASE2","title":"Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases","status":"TERMINATED","sponsor":"Liza Villaruz, MD","startDate":"2023-08-10","conditions":"Non-small Cell Lung Cancer","enrollment":3},{"nctId":"NCT06576635","phase":"NA","title":"LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2024-12-16","conditions":"NSCLC","enrollment":29},{"nctId":"NCT07351565","phase":"PHASE1","title":"Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2026-01-10","conditions":"Non-Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT07271602","phase":"PHASE2","title":"A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-01-30","conditions":"Non Small Cell Lung Cancer, Immunotherapy, Radiotherapy","enrollment":104},{"nctId":"NCT06280196","phase":"PHASE3","title":"A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC","status":"TERMINATED","sponsor":"Bio-Thera Solutions","startDate":"2024-07-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":162},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":218},{"nctId":"NCT05690945","phase":"PHASE3","title":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-02-15","conditions":"Lung Cancer","enrollment":606},{"nctId":"NCT06927986","phase":"PHASE3","title":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","status":"RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-30","conditions":"EGFR-mutated Locally Advanced or Metastatic NSCLC","enrollment":380},{"nctId":"NCT06212752","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-13","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":39},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT06462222","phase":"PHASE1, PHASE2","title":"Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2024-06-30","conditions":"Leptomeningeal Metastasis","enrollment":45},{"nctId":"NCT06385678","phase":"PHASE1, PHASE2","title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-07-05","conditions":"Advanced KRAS G12D Mutant Solid Tumors","enrollment":47},{"nctId":"NCT05722015","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-14","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":377},{"nctId":"NCT07157956","phase":"PHASE1, PHASE2","title":"CVL006 Combination Therapy in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Convalife (Shanghai) Co., Ltd.","startDate":"2025-09-10","conditions":"Advanced Solid Tumor","enrollment":318},{"nctId":"NCT06505837","phase":"PHASE3","title":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-07-11","conditions":"Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer","enrollment":395},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07131345","phase":"PHASE1, PHASE2","title":"Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center, China","startDate":"2025-09-01","conditions":"Malignant Mesothelioma, Mesothelioma","enrollment":55},{"nctId":"NCT04680988","phase":"PHASE2","title":"A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-05","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":194},{"nctId":"NCT07092202","phase":"PHASE4","title":"Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-04-15","conditions":"Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy","enrollment":40},{"nctId":"NCT06738251","phase":"PHASE3","title":"A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-02-12","conditions":"Advanced Urothelial Carcinoma","enrollment":402},{"nctId":"NCT06617936","phase":"PHASE2","title":"Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"Hua Zhang","startDate":"2024-08-27","conditions":"Unresectable Non-small Cell Lung Cancer","enrollment":36},{"nctId":"NCT06969027","phase":"PHASE2","title":"JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-06-19","conditions":"Non-small Cell Lung Cancer","enrollment":84},{"nctId":"NCT04905316","phase":"PHASE2","title":"A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Non-small Cell Lung Cancer","enrollment":41},{"nctId":"NCT03970746","phase":"PHASE1, PHASE2","title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"PDC*line Pharma SAS","startDate":"2019-09-10","conditions":"Non Small Cell Lung Cancer","enrollment":73},{"nctId":"NCT06762080","phase":"PHASE1, PHASE2","title":"Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-03-07","conditions":"Leptomeningeal Metastasis","enrollment":36},{"nctId":"NCT06809517","phase":"PHASE1, PHASE2","title":"Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-03-18","conditions":"Leptomeningeal Metastasis, Intrathecal Drug Delivery","enrollment":34},{"nctId":"NCT06809530","phase":"PHASE1, PHASE2","title":"Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-03-17","conditions":"Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor","enrollment":34},{"nctId":"NCT06659042","phase":"PHASE2","title":"Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-11-20","conditions":"Lung Cancer, Non-Small Cell","enrollment":32},{"nctId":"NCT05096663","phase":"PHASE2, PHASE3","title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2022-03-15","conditions":"Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8","enrollment":82},{"nctId":"NCT05289908","phase":"PHASE1, PHASE2","title":"Intrathecal Pemetrexed for Leptomeningeal Metastasis","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2022-02-21","conditions":"Leptomeningeal Metastases","enrollment":34},{"nctId":"NCT06944470","phase":"PHASE2","title":"JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-04-20","conditions":"NSCLC","enrollment":76},{"nctId":"NCT05209620","phase":"PHASE2","title":"Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-12-21","conditions":"Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT05012254","phase":"PHASE2","title":"Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación GECP","startDate":"2021-11-18","conditions":"Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer","enrollment":71},{"nctId":"NCT06416410","phase":"PHASE3","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-08-07","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":392},{"nctId":"NCT04786964","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","status":"TERMINATED","sponsor":"Checkpoint Therapeutics, Inc.","startDate":"2021-12-08","conditions":"Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT06901817","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases","status":"RECRUITING","sponsor":"Shanghai Cancer Hospital, China","startDate":"2025-03-01","conditions":"Leptomeningeal Metastasis","enrollment":97},{"nctId":"NCT04836728","phase":"PHASE2","title":"Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-03-31","conditions":"Non-small Cell Lung Cancer Metastatic, First-line Treatment","enrollment":156},{"nctId":"NCT06861218","phase":"PHASE2","title":"Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-04","conditions":"Leptomeningeal Metastases","enrollment":42},{"nctId":"NCT03158129","phase":"PHASE2","title":"Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-16","conditions":"Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":101},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT02576574","phase":"PHASE3","title":"Avelumab in First-line NSCLC (JAVELIN Lung 100)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2015-10-29","conditions":"First Line Non-Small Cell Lung Cancer","enrollment":1214},{"nctId":"NCT06758557","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor","status":"RECRUITING","sponsor":"Huabo Biopharm Co., Ltd.","startDate":"2024-01-31","conditions":"Advanced NSCLC, Advanced Endometrial Cancer","enrollment":282},{"nctId":"NCT04605770","phase":"PHASE2","title":"Pemetrexed, Cisplatin With Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2020-12-22","conditions":"Sarcoma,Soft Tissue","enrollment":164},{"nctId":"NCT03872661","phase":"PHASE2","title":"Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-03-01","conditions":"Lung Cancer Stage III","enrollment":36},{"nctId":"NCT04956692","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-08-05","conditions":"Non-Small Cell Lung Cancer","enrollment":531},{"nctId":"NCT06649448","phase":"NA","title":"A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-10-10","conditions":"Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF","enrollment":200},{"nctId":"NCT05487391","phase":"PHASE3","title":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-12-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":632},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT02578680","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-15","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":616},{"nctId":"NCT03971474","phase":"PHASE2","title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2019-05-28","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":166},{"nctId":"NCT06514027","phase":"PHASE2","title":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","status":"NOT_YET_RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2024-07","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT04194203","phase":"PHASE3","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":305},{"nctId":"NCT06474455","phase":"PHASE1, PHASE2","title":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06","conditions":"Advanced Solid Tumors","enrollment":156},{"nctId":"NCT06455046","phase":"PHASE2","title":"Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-10-11","conditions":"Cervical Cancer Recurrent","enrollment":37},{"nctId":"NCT03950674","phase":"PHASE3","title":"Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-22","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":40},{"nctId":"NCT05266846","phase":"PHASE2","title":"Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2024-05-29","conditions":"ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy","enrollment":78},{"nctId":"NCT06431685","phase":"PHASE1","title":"Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-04-25","conditions":"NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT05765084","phase":"PHASE1, PHASE2","title":"Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-02-24","conditions":"Malignant Pleural Mesothelioma","enrollment":15},{"nctId":"NCT06109454","phase":"","title":"Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery","status":"RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2024-03-21","conditions":"Non-small Cell Lung Cancer","enrollment":240},{"nctId":"NCT06399926","phase":"","title":"Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-10-30","conditions":"Leptomeningeal Metastasis, Lung Cancer","enrollment":64},{"nctId":"NCT04147351","phase":"PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-04-10","conditions":"NSCLC Stage IIIB~IV","enrollment":22},{"nctId":"NCT06356701","phase":"PHASE1","title":"Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2024-04-15","conditions":"Long-Term Effects Secondary to Cancer Therapy","enrollment":120},{"nctId":"NCT06328049","phase":"PHASE2","title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC","status":"RECRUITING","sponsor":"Taixing People's Hospital","startDate":"2023-08-10","conditions":"NSCLC","enrollment":30},{"nctId":"NCT02654587","phase":"PHASE3","title":"OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure","status":"TERMINATED","sponsor":"OSE Immunotherapeutics","startDate":"2016-02-12","conditions":"Non Small Cell Lung Cancer","enrollment":219},{"nctId":"NCT05329025","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-06-01","conditions":"Non-small-cell Lung Cancer","enrollment":100},{"nctId":"NCT06136910","phase":"PHASE1, PHASE2","title":"Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-05-09","conditions":"Untreated Advanced Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06116240","phase":"PHASE1","title":"A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-09-02","conditions":"Solid Tumor","enrollment":135},{"nctId":"NCT02439450","phase":"PHASE1, PHASE2","title":"A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Heat Biologics","startDate":"2015-04-15","conditions":"Non-small Cell Lung Cancer","enrollment":121},{"nctId":"NCT03513666","phase":"PHASE2","title":"A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2018-04-09","conditions":"NSCLC","enrollment":40},{"nctId":"NCT01107626","phase":"PHASE3","title":"Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2010-10-25","conditions":"Lung Cancer","enrollment":1516},{"nctId":"NCT05918107","phase":"PHASE2","title":"A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM","status":"RECRUITING","sponsor":"Biotheus Inc.","startDate":"2022-08-13","conditions":"MPM","enrollment":55},{"nctId":"NCT02607423","phase":"PHASE2","title":"Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery","status":"WITHDRAWN","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2015-11-19","conditions":"Stage IIIA Non-Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT05754853","phase":"PHASE3","title":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Shanghai Miracogen Inc.","startDate":"2023-04-06","conditions":"Advanced or Metastatic Urothelium Cancer","enrollment":290},{"nctId":"NCT04396457","phase":"PHASE2","title":"Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901","status":"UNKNOWN","sponsor":"National Hospital Organization Nagoya Medical Center","startDate":"2020-05-25","conditions":"Non-squamous Non-small-cell Lung Cancer, Cancer, Lung","enrollment":50},{"nctId":"NCT02041533","phase":"PHASE3","title":"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-03-27","conditions":"Stage IV or Recurrent Non-Small Cell Lung Cancer","enrollment":541},{"nctId":"NCT04265534","phase":"PHASE2","title":"KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC","status":"TERMINATED","sponsor":"Calithera Biosciences, Inc","startDate":"2020-07-24","conditions":"Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung","enrollment":40},{"nctId":"NCT05416775","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-08-15","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":168}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":1,"reaction":"FEBRILE NEUTROPENIA"},{"count":1,"reaction":"HEPATIC FUNCTION ABNORMAL"},{"count":1,"reaction":"IMMUNE SYSTEM DISORDER"},{"count":1,"reaction":"MYELOSUPPRESSION"},{"count":1,"reaction":"ORAL MUCOSAL EXFOLIATION"},{"count":1,"reaction":"PLATELET COUNT DECREASED"},{"count":1,"reaction":"RASH"},{"count":1,"reaction":"RASH ERYTHEMATOUS"},{"count":1,"reaction":"RASH PRURITIC"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pemetrexed Disodium"],"phase":"phase_3","status":"active","brandName":"Pemetrexed Disodium for Injection","genericName":"Pemetrexed Disodium for Injection","companyName":"Allist Pharmaceuticals, Inc.","companyId":"allist-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pemetrexed is a folate antagonist that inhibits multiple enzymes involved in nucleotide synthesis, disrupting DNA and RNA production in cancer cells. Used for Metastatic non-small cell lung cancer, Malignant pleural mesothelioma, Locally advanced or metastatic urothelial cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}